Cargando…

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy

We retrospective analyzed triple negative breast cancer (TNBC) patients who received either taxane-based or anthracycline-based neoadjuvant chemotherapy, evaluated whether pathological complete response (pCR) is a surrogate endpoint for relapse free survival (RFS) in TNBC and explored which subgroup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, JunJie, Chen, Sheng, Chen, CanMing, Di, GenHong, Liu, GuangYu, Wu, Jiong, Shao, ZhiMin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392337/ https://www.ncbi.nlm.nih.gov/pubmed/27191991 http://dx.doi.org/10.18632/oncotarget.9369

Ejemplares similares

The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation
por: Li, Jun-jie, et al.
Publicado: (2014)

Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
por: Huang, Ou, et al.
Publicado: (2009)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients
por: Lin, Yanping, et al.
Publicado: (2009)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Is Pathologic Complete Response the Surrogate in Primary Gastric Angiosarcoma Undergoing Doxorubicin-Based Neoadjuvant Chemotherapy? A Case Report
por: Zheng, Chun-Hui, et al.
Publicado: (2020)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing
por: Qiu, Jiajia, et al.
Publicado: (2016)

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Huang, Liang, et al.
Publicado: (2013)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
por: Zheng, Shuyue, et al.
Publicado: (2022)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
por: Fournier, Marcia V., et al.
Publicado: (2019)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

Pathological Complete Response in Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy: Survival Outcome and Its Relevance as a Surrogate End Point
por: Agarwal, Reshu, et al.
Publicado: (2020)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
por: Weiss, Anna, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
por: Li, Junjie, et al.
Publicado: (2022)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients
por: You, Chao, et al.
Publicado: (2017)

Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer
por: Chen, Yong-He, et al.
Publicado: (2020)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy
por: Chen, Sheng, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer
por: Chen, Sheng, et al.
Publicado: (2012)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
por: Vidra, Radu, et al.
Publicado: (2022)

A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Chung, Wai-Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mh02i2gvh95vpc25mbjqeld5nv